Should I buy or sell Bioventus stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Bioventus in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" BVS shares. View BVS analyst ratings or view top-rated stocks .

What is Bioventus' stock price target for 2024?

3 Wall Street analysts have issued 12-month target prices for Bioventus' stock. Their BVS share price targets range from $7.00 to $9.00. On average, they expect the company's share price to reach $7.67 in the next year. This suggests a possible upside of 63.1% from the stock's current price. View analysts price targets for BVS or view top-rated stocks among Wall Street analysts .

How have BVS shares performed in 2024?

Bioventus' stock was trading at $5.27 at the beginning of the year. Since then, BVS stock has decreased by 10.8% and is now trading at $4.70. View the best growth stocks for 2024 here .

When is Bioventus' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 21st 2024. View our BVS earnings forecast .

How were Bioventus' earnings last quarter?

Bioventus Inc. (NYSE:BVS) released its quarterly earnings data on Tuesday, March, 12th. The company reported $0.07 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.06 by $0.01. The company earned $135.42 million during the quarter, compared to analysts' expectations of $124.84 million. Bioventus had a positive trailing twelve-month return on equity of 2.25% and a negative net margin of 30.49%.

What guidance has Bioventus issued on next quarter's earnings?

Bioventus updated its FY 2024 earnings guidance on Tuesday, March, 12th. The company provided earnings per share (EPS) guidance of 0.120-0.200 for the period, compared to the consensus EPS estimate of 0.330. The company issued revenue guidance of $520.0 million-$535.0 million, compared to the consensus revenue estimate of $517.8 million.

When did Bioventus IPO?

Bioventus (BVS) raised $126 million in an initial public offering (IPO) on Thursday, February 11th 2021. The company issued 7,400,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley, J.P. Morgan, Goldman Sachs and Canaccord Genuity acted as the underwriters for the IPO.

Who are Bioventus' major shareholders?

Bioventus' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include GSG Advisors LLC (0.03%). Insiders that own company stock include Anthony D'adamio , Anthony P Bihl III, John A Bartholdson, John Nosenzo, Juniper Investment Company, Ll, Katrina J Church, Kenneth Michael Reali , Mark Leonard Singleton and William A Hawkins. View institutional ownership trends .

How do I buy shares of Bioventus?

Shares of BVS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NYSE:BVS

Bioventus (BVS) Stock Price, News & Analysis

→ [Urgent!] Generational Wealth Gameplan (From Crypto 101 Media) (Ad)

Free BVS Stock Alerts

$4.70

+0.06 (+1.29%)

(As of 04/17/2024 ET)

Compare

Today's Range: $4.57
▼
$4.86
50-Day Range: $4.37
▼
$5.75
52-Week Range: $0.86
▼
$6.08

Volume: 125,526 shs
Average Volume: 147,697 shs
Market Capitalization: $372.08 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $7.67

Get Bioventus alerts:

Bioventus MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 63.1% Upside
$7.67 Price Target
Short Interest: N/A
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.58
Based on 7 Articles This Week
Insider Trading: Selling Shares
$80,435 Sold Last Quarter
Proj. Earnings Growth: 150.00%
From $0.16 to $0.40 Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.66 out of 5 stars

Medical Sector

264th out of 912 stocks

Medical Devices Industry

2nd out of 5 stocks

3.5

Analyst's Opinion

Consensus Rating
Bioventus has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Bioventus has only been the subject of 1 research reports in the past 90 days.

N/A

Short Interest

Short Interest
There is no current short interest data available for BVS.

0.0

Dividend Strength

Dividend Yield
Bioventus does not currently pay a dividend.
Dividend Growth
Bioventus does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for BVS.

3.1

News and Social Media Coverage

News Sentiment
Bioventus has a news sentiment score of 0.58. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.41 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 7 news articles for Bioventus this week, compared to 1 article on an average week.
MarketBeat Follows
3 people have added Bioventus to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days.

4.2

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Bioventus insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $80,435.00 in company stock.
Percentage Held by Insiders
29.10% of the stock of Bioventus is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
62.94% of the stock of Bioventus is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.9

Earnings and Valuation

Earnings Growth
Earnings for Bioventus are expected to grow by 150.00% in the coming year, from $0.16 to $0.40 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Bioventus is -1.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Bioventus is -1.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Bioventus has a P/B Ratio of 1.68. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Crypto 101 Media

[Urgent!] Generational Wealth Gameplan

A brand-new guide from the host of one of the world's largest cryptocurrency podcasts lays out an action plan that could help you retire quickly and comfortably in today's crypto market.

Click here to get instant access to the guide

About Bioventus Stock (NYSE:BVS)

Bioventus Inc., a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain. Its surgical solutions comprise bone graft substitutes that increase bone formation to stimulate bone healing in spinal fusions and other orthopedic surgeries; and ultrasonic products used for precise bone cutting and sculpting, soft tissue management, and tissue debridement, in various surgeries, including minimally invasive applications. The company's product include, Osteoamp, an allograft-derived bone graft for bone grafting procedures; Exponent matrix for posterolateral spine procedures; Purebone for bone grafting procedures; Signafuse bone graft; Interfuse bone graft; Osteomatrix+ synthetic bone graft; Extractor for autologous cell and bone marrow extraction; reficio bone matrix; nexus ultrasonic surgical system; bonescalpel surgical solution; SonaStar for surgical procedures; and SonicOne ultrasonic cleansing and debridement system. The company's restorative therapies include a bone stimulation system and devices to help patients regain leg or hand function due to stroke, multiple sclerosis, or other central nervous system disorders. Its products include exogen, a bone healing system; L300 GO, a foot drop system; H200 rehabilitation system; Vector, a body weight support system; and Bioness integrated therapy system. It developing Talisman pulse generator and receiver for peripheral nerve stimulation. The company was founded in 2011 and is headquartered in Durham, North Carolina.

BVS Stock Price History

30 days | 90 days | 365 days | Advanced Chart

BVS Stock News Headlines

April 16, 2024 | insidertrades.com

Insider Selling: Bioventus Inc. (NYSE:BVS) SVP Sells 3,054 Shares of Stock

March 26, 2024 | insidertrades.com

Bioventus Inc. (NYSE:BVS) CFO Sells $29,865.99 in Stock

April 18, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

March 21, 2024 | insidertrades.com

Bioventus Inc. (NYSE:BVS) SVP Anthony D'adamio Sells 3,125 Shares

April 17, 2024 | investing.com

Bioventus CFO sells shares worth $19,000

April 16, 2024 | americanbankingnews.com

Bioventus Inc. (NYSE:BVS) SVP Anthony D'adamio Sells 3,054 Shares of Stock

April 16, 2024 | americanbankingnews.com

Bioventus Inc. (NYSE:BVS) CFO Mark Leonard Singleton Sells 4,000 Shares of Stock

March 13, 2024 | bizjournals.com

Durham public company resets priorities under new CEO

April 18, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

March 13, 2024 | finance.yahoo.com

Bioventus Inc. (NASDAQ:BVS) Q4 2023 Earnings Call Transcript

March 12, 2024 | markets.businessinsider.com

What Wall Street expects from Repro Medical System's earnings

March 12, 2024 | msn.com

Bioventus Non-GAAP EPS of $0.07 beats by $0.05, revenue of $135.42M beats by $11.46M

March 12, 2024 | finance.yahoo.com

Bioventus Inc (BVS) Reports Growth in Q4 Sales and Adjusted EBITDA, Provides Optimistic 2024 ...

March 12, 2024 | globenewswire.com

Bioventus Announces Fourth Quarter and Full Year 2023 Financial Results

March 12, 2024 | nz.finance.yahoo.com

Bioventus Inc. (BVS) stock price, news, quote & history – Yahoo Finance

March 11, 2024 | benzinga.com

A Preview Of Bioventus's Earnings

March 4, 2024 | globenewswire.com

Bioventus to Report Fourth Quarter of Fiscal Year 2023 Financial Results on March 12, 2024

February 15, 2024 | wsj.com

Bioventus Inc. Cl A

January 24, 2024 | seekingalpha.com

Bioventus: Bullish On Path To Profitability

January 19, 2024 | finanznachrichten.de

Bioventus, Inc.: Bioventus Enters into an Amendment with its Credit Agreement Lenders to Enhance Financial and Operational Flexibility

January 12, 2024 | finance.yahoo.com

Bioventus Announces Inducement Equity to President and Chief Executive Officer Robert Claypoole

December 27, 2023 | businesswire.com

BIOVENTUS ALERT: Bragar Eagel & Squire, P.C. is Investigating Bioventus Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

December 21, 2023 | benzinga.com

Bioventus Stock (NASDAQ:BVS) Dividends: History, Yield and Dates

December 20, 2023 | bizjournals.com

Durham public company names new CEO at critical juncture

December 19, 2023 | finance.yahoo.com

Bioventus Names Robert Claypoole as President and Chief Executive Officer

December 16, 2023 | msn.com

Bioventus Inc - (BVS) Price Target Increased by 34.58% to 6.63

December 8, 2023 | msn.com

Canaccord Genuity Upgrades Bioventus Inc - (BVS)

See More Headlines

Receive BVS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bioventus and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/12/2024
Today: 4/18/2024
Next Earnings (Estimated): 5/21/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NYSE
Sector: Medical
Industry: Medical Devices
Sub-Industry: N/A
Current Symbol: NYSE:BVS
CUSIP: N/A
CIK: 1665988
Web: www.bioventus.com
Phone: 919-474-6700
Fax: N/A
Employees: 970
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $7.67
High Stock Price Target: $9.00
Low Stock Price Target: $7.00
Potential Upside/Downside: +63.1%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.52)
Trailing P/E Ratio: N/A
Forward P/E Ratio: 29.38
P/E Growth: N/A
Net Income: $-156,230,000.00
Net Margins: -30.49%
Pretax Margin: -23.64%
Return on Equity: 2.25%
Return on Assets: 0.62%

Debt

Debt-to-Equity Ratio: 1.66
Current Ratio: 1.53
Quick Ratio: 1.01

Sales & Book Value

Annual Sales: $512.35 million
Price / Sales: 0.73
Cash Flow: $0.80 per share
Price / Cash Flow: 5.85
Book Value: $2.80 per share
Price / Book: 1.68

Miscellaneous

Outstanding Shares: 79,166,000
Free Float: 56,129,000
Market Cap: $372.08 million
Optionable: Not Optionable
Beta: 0.50

7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives

Mr. Mark L. Singleton (Age 54)
Senior VP & CFO
Comp: $444.12k
Mr. Robert Claypoole (Age 52)
President, CEO & Director
Mr. Mike Crowe B.S.
M.B.A., Senior Vice President of Operations
Mr. David Crawford
Vice President of Investor Relations & Treasurer
Mr. Anthony D'Adamio (Age 63)
Senior VP, General Counsel & Corporate Secretary
Comp: $618.29k
Ms. Katrina J. Church J.D. (Age 62)
Senior VP & Chief Compliance Officer
Ms. Helen Leupold
Senior VP & Chief Human Resources Officer
Mr. Larry Chen
Managing Director of China & Asia Pacific

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

BVS Stock Analysis - Frequently Asked Questions

Should I buy or sell Bioventus stock right now?: 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Bioventus in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" BVS shares.
View BVS analyst ratings or view top-rated stocks.
What is Bioventus' stock price target for 2024?: 3 Wall Street analysts have issued 12-month target prices for Bioventus' stock. Their BVS share price targets range from $7.00 to $9.00. On average, they expect the company's share price to reach $7.67 in the next year. This suggests a possible upside of 63.1% from the stock's current price.
View analysts price targets for BVS or view top-rated stocks among Wall Street analysts.
How have BVS shares performed in 2024?: Bioventus' stock was trading at $5.27 at the beginning of the year. Since then, BVS stock has decreased by 10.8% and is now trading at $4.70.
View the best growth stocks for 2024 here.
When is Bioventus' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 21st 2024.
View our BVS earnings forecast.
How were Bioventus' earnings last quarter?: Bioventus Inc. (NYSE:BVS) released its quarterly earnings data on Tuesday, March, 12th. The company reported $0.07 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.06 by $0.01. The company earned $135.42 million during the quarter, compared to analysts' expectations of $124.84 million. Bioventus had a positive trailing twelve-month return on equity of 2.25% and a negative net margin of 30.49%.

What guidance has Bioventus issued on next quarter's earnings?: Bioventus updated its FY 2024 earnings guidance on Tuesday, March, 12th. The company provided earnings per share (EPS) guidance of 0.120-0.200 for the period, compared to the consensus EPS estimate of 0.330. The company issued revenue guidance of $520.0 million-$535.0 million, compared to the consensus revenue estimate of $517.8 million.
When did Bioventus IPO?: Bioventus (BVS) raised $126 million in an initial public offering (IPO) on Thursday, February 11th 2021. The company issued 7,400,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley, J.P. Morgan, Goldman Sachs and Canaccord Genuity acted as the underwriters for the IPO.
Who are Bioventus' major shareholders?: Bioventus' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include GSG Advisors LLC (0.03%). Insiders that own company stock include Anthony D'adamio, Anthony P Bihl III, John A Bartholdson, John Nosenzo, Juniper Investment Company, Ll, Katrina J Church, Kenneth Michael Reali, Mark Leonard Singleton and William A Hawkins.
View institutional ownership trends.
How do I buy shares of Bioventus?: Shares of BVS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSE:BVS) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Bioventus (BVS) Stock Price, News & Analysis

Bioventus MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Short Interest

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Bioventus Stock (NYSE:BVS)

BVS Stock Price History

BVS Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

BVS Stock Analysis - Frequently Asked Questions

Overall MarketRank^™